Skybiotech Healt

{
  "main_header": {
    "sid": 364572,
    "name": "Skybiotech Healt",
    "stock_name": "Skybiotech Healt",
    "full_name": "Skybiotech Healthcare Limited",
    "name_url": "stocks-analysis/skybiotech-healt",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "160.15",
    "chg": 3.15,
    "chgp": "2.01%",
    "dir": 1,
    "prev_price": "157.00",
    "mcapval": "30.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 512036,
    "symbol": "",
    "ind_name": "Garments & Apparels",
    "ind_code": 67,
    "sector_id": 32,
    "indexname": "India SENSEX",
    "isin": "INE393H01016",
    "curr_date": "Jul 24, 03:30 PM",
    "curr_time": "15:37 PM",
    "last_traded_at": "Jul 24, 03:30 PM IST",
    "bse_nse_vol": "461 ",
    "exc_status": "Active",
    "traded_date": "Jul 24, 2026",
    "traded_date_str": "2026 07 24",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/skybiotech-healt-364572-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Skybiotech Healthcare Limited Upgraded to Sell on Technical Improvements Despite Weak Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/skybiotech-healthcare-limited-upgraded-to-sell-on-technical-improvements-despite-weak-fundamentals-4118760",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/SkybiotechHealt_mojoScore_4118760.png",
        "date": "2026-07-24 08:21:29",
        "description": "Skybiotech Healthcare Limited, a micro-cap player in the Garments & Apparels sector, has seen its investment rating upgraded from Strong Sell to Sell as of 23 July 2026. This change reflects a nuanced shift in the company’s technical outlook amid persistently weak financial fundamentals and valuation concerns. Investors should weigh the improved technical signals against the company’s ongoing operational challenges before making decisions."
      },
      {
        "title": "Skybiotech Healthcare Limited is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/skybiotech-healthcare-limited-is-rated-strong-sell-4084686",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/SkybiotechHealt_mojoScore_4084686.png",
        "date": "2026-07-02 10:10:53",
        "description": "Skybiotech Healthcare Limited is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 Dec 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 02 July 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and technical outlook."
      },
      {
        "title": "Skybiotech Healthcare Limited is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/skybiotech-healthcare-limited-is-rated-strong-sell-4060979",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/SkybiotechHealt_mojoScore_4060979.png",
        "date": "2026-06-18 10:11:09",
        "description": "Skybiotech Healthcare Limited is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 Dec 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 18 June 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Are Skybiotech Healthcare Limited latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-skybiotech-healthcare-limited-latest-results-good-or-bad-4032493",
        "imagepath": "",
        "date": "2026-06-02 19:39:02",
        "description": "Skybiotech Healthcare Limited's latest financial results for Q4 FY26 present a mixed picture, highlighting both operational challenges and some signs of revenue recovery. The company reported net sales of ₹1.83 crores, which reflects a significant quarter-on-quarter increase of 90.63%. However, this growth comes after a previous decline, indicating volatility in revenue generation. Year-on-year, the revenue also shows a notable increase of 79.41% compared to ₹1.02 crores in Q4 FY25.\n\nDespite the revenue growth, the company's operational struggles are evident. Skybiotech recorded a net loss of ₹0.30 crores, which is a 37.50% decline from the previous quarter's loss. The operating margin remains deeply negative at -48.09%, suggesting ongoing difficulties in converting sales into profits. The company has now reported negative operating profits for seven consecutive quarters, indicating persistent operational d..."
      },
      {
        "title": "Skybiotech Healthcare Q4 FY26: Mounting Losses Signal Deepening Operational Crisis",
        "link": "https://www.marketsmojo.com/news/result-analysis/skybiotech-healthcare-q4-fy26-mounting-losses-signal-deepening-operational-crisis-4028723",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/SkybiotechHealt_quaterlyResult_4028723.png",
        "date": "2026-06-01 14:35:15",
        "description": "Skybiotech Healthcare Limited, a micro-cap textile manufacturer with a market capitalisation of ₹28.00 crores, reported a net loss of ₹0.30 crores for Q4 FY26, marking the seventh consecutive quarter of losses despite a sharp revenue uptick. The stock surged 5.00% on June 01, 2026, closing at ₹152.25, though this represents a 35.84% decline from its 52-week high of ₹237.30."
      },
      {
        "title": "Are Skybiotech Healthcare Limited latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-skybiotech-healthcare-limited-latest-results-good-or-bad-4023960",
        "imagepath": "",
        "date": "2026-05-30 19:54:23",
        "description": "Skybiotech Healthcare Limited's latest financial results for Q3 FY26 indicate significant operational challenges. The company reported net sales of ₹0.96 crores, reflecting a year-on-year decline of 61.90% from ₹2.52 crores in Q3 FY25, and a quarter-on-quarter contraction of 50.00% from ₹1.92 crores in Q2 FY26. This sharp revenue drop raises concerns about the company's ability to maintain sustainable client engagements or trading opportunities, especially given the previous quarter's decline of 19.67%.\n\nThe net loss for the quarter was ₹0.48 crores, which represents a worsening from the loss of ₹0.31 crores in the prior quarter. The operating margin also deteriorated significantly, standing at negative 45.83%, compared to negative 11.46% in Q2 FY26. This indicates that the company's core operations are incurring substantial losses, consuming capital at an accelerating rate.\n\nSkybiotech's return on equity (..."
      },
      {
        "title": "When is the next results date for Skybiotech Healthcare Limited?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-skybiotech-healthcare-limited-4017599",
        "imagepath": "",
        "date": "2026-05-27 23:17:59",
        "description": "The next results date for Skybiotech Healthcare Limited is scheduled for 30 May 2026...."
      },
      {
        "title": "Skybiotech Healthcare Limited is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/skybiotech-healthcare-limited-is-rated-strong-sell-3991079",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SkybiotechHealt_mojoScore_3991079.png",
        "date": "2026-05-14 10:10:32",
        "description": "Skybiotech Healthcare Limited is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 14 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      }
    ],
    "total": 190,
    "sid": "364572",
    "stock_news_url": "https://www.marketsmojo.com/news/No announcements on  in the last one month-364572"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "19-Jul-2026",
      "details": "Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulation",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "27-Jun-2026",
      "details": "Intimation of Trading Window Closure to consider and approve un-audited financial results for the quarter ended on 30th June 2026",
      "source": "BSE"
    },
    {
      "caption": "Results Financials For The Year Ended On 31St March 2026",
      "datetime": "30-May-2026",
      "details": "Submission of Financial Results for the Quarter and Year ended on 31st March 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Skybiotech Healthcare Limited Upgraded to Sell on Technical Improvements Despite Weak Fundamentals

2026-07-24 08:21:29

Skybiotech Healthcare Limited, a micro-cap player in the Garments & Apparels sector, has seen its investment rating upgraded from Strong Sell to Sell as of 23 July 2026. This change reflects a nuanced shift in the company’s technical outlook amid persistently weak financial fundamentals and valuation concerns. Investors should weigh the improved technical signals against the company’s ongoing operational challenges before making decisions.

Read full news article

Skybiotech Healthcare Limited is Rated Strong Sell

2026-07-02 10:10:53

Skybiotech Healthcare Limited is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 Dec 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 02 July 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Read full news article

Skybiotech Healthcare Limited is Rated Strong Sell

2026-06-18 10:11:09

Skybiotech Healthcare Limited is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 Dec 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 18 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Are Skybiotech Healthcare Limited latest results good or bad?

2026-06-02 19:39:02

Skybiotech Healthcare Limited's latest financial results for Q4 FY26 present a mixed picture, highlighting both operational challenges and some signs of revenue recovery. The company reported net sales of ₹1.83 crores, which reflects a significant quarter-on-quarter increase of 90.63%. However, this growth comes after a previous decline, indicating volatility in revenue generation. Year-on-year, the revenue also shows a notable increase of 79.41% compared to ₹1.02 crores in Q4 FY25. Despite the revenue growth, the company's operational struggles are evident. Skybiotech recorded a net loss of ₹0.30 crores, which is a 37.50% decline from the previous quarter's loss. The operating margin remains deeply negative at -48.09%, suggesting ongoing difficulties in converting sales into profits. The company has now reported negative operating profits for seven consecutive quarters, indicating persistent operational d...

Read full news article

Skybiotech Healthcare Q4 FY26: Mounting Losses Signal Deepening Operational Crisis

2026-06-01 14:35:15

Skybiotech Healthcare Limited, a micro-cap textile manufacturer with a market capitalisation of ₹28.00 crores, reported a net loss of ₹0.30 crores for Q4 FY26, marking the seventh consecutive quarter of losses despite a sharp revenue uptick. The stock surged 5.00% on June 01, 2026, closing at ₹152.25, though this represents a 35.84% decline from its 52-week high of ₹237.30.

Read full news article

Are Skybiotech Healthcare Limited latest results good or bad?

2026-05-30 19:54:23

Skybiotech Healthcare Limited's latest financial results for Q3 FY26 indicate significant operational challenges. The company reported net sales of ₹0.96 crores, reflecting a year-on-year decline of 61.90% from ₹2.52 crores in Q3 FY25, and a quarter-on-quarter contraction of 50.00% from ₹1.92 crores in Q2 FY26. This sharp revenue drop raises concerns about the company's ability to maintain sustainable client engagements or trading opportunities, especially given the previous quarter's decline of 19.67%. The net loss for the quarter was ₹0.48 crores, which represents a worsening from the loss of ₹0.31 crores in the prior quarter. The operating margin also deteriorated significantly, standing at negative 45.83%, compared to negative 11.46% in Q2 FY26. This indicates that the company's core operations are incurring substantial losses, consuming capital at an accelerating rate. Skybiotech's return on equity (...

Read full news article

When is the next results date for Skybiotech Healthcare Limited?

2026-05-27 23:17:59

The next results date for Skybiotech Healthcare Limited is scheduled for 30 May 2026....

Read full news article

Skybiotech Healthcare Limited is Rated Strong Sell

2026-05-14 10:10:32

Skybiotech Healthcare Limited is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 14 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

View All News